Newsroom | 88970 results

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. “We are thrilled to have Daniel join Johnson & Johnson’s Board of Directors,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel’s unique perspective and wealth of experience wi...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 8,400 shares of the Company’s common stock at an exercise price per share of $9.85, which was the closing price on June 9, 2025, and restri...

CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), la compañía líder en terapias de ARN de interferencia (ARNi), ha anunciado hoy que la Comisión Europea (CE) ha concedido la aprobación para el tratamiento de la amiloidosis de transtiretina común o hereditaria en pacientes adultos con cardiomiopatía (ATTR-CM) como indicación adicional para su terapia huérfana de ARNi AMVUTTRA® (vutrisiran). El comunicado en el idioma original es la versión oficial y autoriz...

HONG KONG--(BUSINESS WIRE)--Reynold Lemkins Group, an international investment firm focused on value-driven cross-border capital deployment, announced the continued advancement of its strategic focus in late-stage healthcare, AI-powered therapeutics, and Asia-centered biotech commercialization. As part of this strategy, Reynold Lemkins recently participated in the IPO of VISEN Pharmaceuticals on the Hong Kong Stock Exchange (HKEX: 02561). VISEN, a biopharmaceutical company specializing in long-...

BOSTON--(BUSINESS WIRE)--20/20 Onsite, the leading provider of point-of-need ophthalmic services for clinical trials, announces the deployment of its latest mobile vision clinic, bringing its fleet to 16 units, including a mix of mobile clinics, pods, and suites. The new unit hit the road in early May and is now fully operational, enabling 20/20 Onsite to support a higher tempo of decentralized and hybrid clinical trials nationwide. This milestone reinforces 20/20 Onsite’s ability to scale with...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 17, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2025 and enter the 16-digit control number found in their proxy mat...

DUBLIN--(BUSINESS WIRE)--The "Preimplantation Genetic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to ResearchAndMarkets.com's offering. The Preimplantation Genetic Testing Market was valued at USD 0.66 Billion in 2024 and is expected to reach USD 1.05 Billion by 2030, rising at a CAGR of 8.20%. Preimplantation Genetic Testing (PGT) is a pivotal procedure within assisted reproductive technologies, primarily used during in vitro fert...

DUBLIN--(BUSINESS WIRE)--The "Cloning & Mutagenesis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to ResearchAndMarkets.com's offering. The Cloning & Mutagenesis Market was valued at USD 2.67 Billion in 2024 and is expected to reach USD 7.58 Billion by 2030, rising at a CAGR of 18.99%. This market is witnessing rapid growth, largely fueled by expanding applications of cloning techniques in fields such as genetic and reproductive rese...

NEW YORK--(BUSINESS WIRE)--EDETEK Inc., a global provider of leading AI-driven clinical development platforms and services, has engaged Capgemini to support its ongoing advancements in digital transformation within the life sciences industry. This engagement combines EDETEK’s deep domain expertise and established platforms and services with Capgemini’s advanced AI and engineering capabilities, to enable EDETEK to deliver innovative solutions aimed at optimizing clinical development, improving o...